Search

Background: Ductal carcinoma in situ with microinvasion (DCIS-MI) is a subtype of breast cancer with good prognosis, for which both breast conserving surgery plus radiotherapy (BCS+RT) and mastectomy are feasible surgical methods, but their effects on the prognosis of patients are still unclear. Methods: We used the Surveillance, Epidemiology and End Results (SEER) database to extracted DCIS-MI patients who underwent BCS+RT or mastectomy between 2000 and 2014. Participants were divided into BCS+RT group and mastectomy group. We compared the breast cancer-specific survival (BCSS) and overall survival (OS) of the two groups using Kaplan -Meier method and Cox proportional hazard regressions before and after propensity score matching (PSM) with the landmark. Results: We selected 5432 patients, among which 2834 patients (52.17%) were in the BCS+RT group and 2598 patients (47.83%) were in the mastectomy group. With a 101 months median follow-up time in the overall cohort, both univariate and multivariate analysis showed that BCS + RT group showed significantly higher OS and BCSS compared with patients in the mastectomy group (PPP= 0.017). In addition, the subgroup analysis showed that BCS + RT is at least equivalent to mastectomy with respect to OS and BCSS in any subgroup. Conclusion: For patients with DCIS-MI, the prognosis of BCS+RT was superior to mastectomy.

Background: The effect of postmastectomy radiotherapy (PMRT) on T1-2N1M0 triple-negative breast cancers (TNBC) remains unclear. The population-based study aimed to investigate the survival outcomes of T1-2N1M0 TNBC patients who underwent PMRT or not. Methods: We selected 1743 patients with T1-2N1M0 TNBC who underwent mastectomy between 2010 and 2015 through the Surveillance, Epidemiology and End Results (SEER) database. After propensity score matching (PSM) , the PMRT and no-PMRT groups consisted of 586 matched patients, respectively.The Kaplan-Meier method was applied to calculate breast cancer-specific survival (BCSS) and cox proportional hazard model were used to determine the prognostic factors of T1-2N1M0 TNBC.Results: The 5-year BCSS for the PMRT group and no-PMRT group was 79.1% and 74.7%, respectively. TNBC patients with stage T1-2N1M0 receiving PMRT did not show better BCSS than those did not (HR =0.800, 95% CI =0.605-1.056, P =0.115). Subgroup analysis showed that in patients with three nodes positive, radiotherapy could significantly improve BCSS(HR=0.396, 95% CI = 0.175-0.900, P = 0.027), but it brought no significant advantage in BCSS in patients with one or two nodes positive(HR =1.061, 95% CI =0.725-1.552, P =0.761; HR =0.657, 95% CI =0.405-1.065, P =0.088).In addition, PMRT improves the BCSS in TNBC patients with T2 tumor concomitant with three positive lymph nodes(HR =0.343, 95% CI =0.132-0.890, P =0.028).Conclusion: TNBC patients with T2 tumor concomitant with three positive lymph node can benefit from PMRT.

Background: The prognostic impact of tumor location on breast cancer patients is not consistent and still controversial. We aimed to investigate the prognostic role of primary tumor location on the survival of patients with breast cancer. Methods: Using the Surveillance, Epidemiology, and End Results database, we identified 53,905 patients diagnosed with tumors in the lower quadrants (n=11,065), upper quadrants (n=38,974), or central and nipple (n=3,866). Chi-squared test was used to compare categorical variables across the groups. Cox proportional hazard models were applied to estimate the factors associated with prognosis.Results: Compared with the other quadrants, patients with central and nipple lesions showed generally more unfavorable clinicopathologic features and worse breast cancer-specific survival (BCSS) and overall survival (OS). Multivariate Cox analysis showed a higher hazard ratio (HR) for tumor location of central and nipple (BCSS: HR, 1.145, p = 0.036, 95% confidence interval [CI], 1.009-1.299; OS: HR, 1.118, p = 0.024, 95% CI: 1.015-1.232), while lower HR were observed for upper quadrants (BCSS: HR, 0.888, p = 0.004, 95% CI: 0.818-0.964; OS: HR, 0.930, p = 0.023, 95% CI: 0.873-0.990). Multivariate logistic regression indicated that tumors located in central and nipple were more likely to be inoperable disease (HR, 1.460, 95% CI: 1.300-1.640, p < 0.001), while tumors located in upper quadrants tend to be operable disease (HR, 0.895, p = 0.005, 95% CI, 0.829-0.967).Conclusion: Tumors located in central and nipple had negative contact with BCSS and OS, while tumor located in upper quadrants had favorable contact with survival.

Objective: To study the correlation of serum HMGA1 levels in breast cancer lesion and serum with the pathological features of tumor. Methods: The patients with breast cancer and those with benign breast tumor who were treated in Mianyang Central Hospital between August 2014 and October 2017 were selected as the malignant group and the benign group of the study respectively; serum was collected to determine HMGA1 level, and breast cancer lesions and benign tumor breast tumor lesions were collected to determine the level of HMGA1 as well as the expression of proliferation genes and invasion genes. Results: HMGA1 level in breast cancer lesion and HMGA1 level in serum of malignant group were significantly higher than those of control group, and HMGA1 level in breast cancer lesion was positively correlated with HMGA1 level in serum; CCN5, MMRN2, TCEAL7 mRNA expression in breast cancer lesions of malignant group were significantly lower than those in breast tumor lesions of benign group, whereas HPK1 and Ki67, Sema4D, RhoA, Gab2, ARK5, SGK3 and MMP9 mRNA expression were significantly higher than those in breast tumor lesions of benign group; CCN5, MMRN2, TCEAL7 mRNA expression in breast cancer lesions of malignant group of patients with high HMGA1 level were significantly lower than those of malignant group of patients with low HMGA1 level, whereas HPK1 and Ki67, Sema4D, RhoA, Gab2, ARK5, SGK3 and MMP9 mRNA expression were significantly higher than those of malignant group of patients with low HMGA1 level. Conclusion: HMGA1 levels abnormally increase in breast cancer lesion and serum; the abnormally elevated HMGA1 can assess the pathological features of tumor proliferation and invasion.

Iron oxidized acidophlies are important in uranium extraction for it mainly depends on the indirect mechanism of bioleaching. Taking indirect field In-Situ bioleaching experiment in a uranium deposit as an example, several strains of acidophiles were isolated from the acid leachate. Bacteria compositions of the samples taken different stages were analyzed by 16SrDNA PCR-RFLP method. Results showed that the dominant bacteria in the leachate wereAcidithiobacillus.ferrivorans,At.ferrooxidansandLeptospirrilum. ferrooxidansfrom the beginning to the middle stage of bioleaching process. With the process carried on, ferric ion concentration increased in the oxidation tanks,L. ferrooxidansbecame predominant bacteria. Again confirmed that in this in-situ bioleaching site, iron oxidized bacteria were in dominant.

A simple synthetic approach for the transformation of ( S )-Ugi's amine, another configuration of ( R )-Ugi's amine, one of the most widely used intermediate in the preparation of chiral ferrocene-based ligands, has been developed via esterification using anhydride, alkaline hydrolysis and active manganese dioxide oxidation, and the corresponding ferrocenyl ketone was afforded in good yields.

To investigate the effectiveness of (131)I-epidermal growth factor (EGF) on the proliferation of a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma.EGF/HAS was labeled with (131)I by chloramines-T method. Human breast cancer xenografts with positive EGFR expression were established in nude mice. The nude mice were injected with normal saline, Epirubicin Hydrochloride, (131)I-EGF, (131)I-HAS, (131)I intravenously and (131)I-EGF intratumoral administration respectively. The tumor growth inhibition rate was determined by measurement of tumor volume. Different examinations were carried out.There was remarkable significant difference of tumor volumes at 26th day among (131)I-EGF trial groups, (131)I, (131)I-HAS, and the negative control group. The tumor growth inhibition rate of (131)I-EGF trial groups was 82.0%, 80.7% respectively. Compared with the negative control group, the (131)I-EGF trial groups remarkably suppressed the growth of tumor (P0.05). Irreversible destruction of tissues in (131)I-EGF groups was observed under light and electron microscope. There was no evidence of hepatotoxicity, renal toxicity and myelotoxicity in nude mice bearing human breast cancer given (131)I-EGF over a 4-wk observation period.(131)I-EGF has obvious antitumor effects on a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma, with little obvious side effects.

This study investigated the inhibitory action of (131)I-recombinant human EGF ((131)I-rhEGF) on MCF-7 human breast cancer tumor development in nude mice. The activity and tumor uptake of (131)I-rhEGF was measured by tissue distribution assay, and its effect on tumor growth was measured by monitoring tumor size after treatment with (131)I-rhEGF. Changes in tumor cell ultrastructure were observed by transmission electron microscopy (TEM), and pathological changes in tumor tissue were observed by light microscopy. The tissue distribution assay revealed that (131)I-rhEGF was markedly absorbed by the tumor and reached its maximal uptake rate (16.73%ID. g(-1)) at 120 hours at which point the drug concentration in the tumor was 11.1-fold, 8.1-fold, and 6.6-fold higher than that in blood, liver, and kidneys, respectively. Tumor size measurements showed that tumor development was significantly inhibited by intravenously and intratumorally injected (131)I-rhEGF. Tumor inhibition rates (82.0% and 80.7%, respectively) were significantly higher than those of tumors treated with (131)I (7.49%) and (131)I-HSA (6.91%; P < 0.05). TEM and light microscopy revealed that intravenous and intratumoral injection of (131)I-rhEGF could significantly damage and ultimately kill tumor cells. Our results suggest that (131)I-rhEGF suppresses development of xenografted breast cancer cells in nude mice, providing a novel candidate for receptor-mediated targeted radiotherapy.

To study the prognostic identification of lymph node negative breast carcinoma by quantitative pathologic technique.Several morphometrical parameters, DNA content of cell nuclei were detected by means of a quantitative pathologic technique on 102 patients with lymph node negative invasive breast duct carcinoma. The effects of potential prognostic factors of lymph node negative breast cancer patients were assessed by Cox's proportional hazards regression model.DNA index, minimal diameter of nuclei, area of nuclei, maximal diameter of nuclei, and the perimeter of nuclei are important factors to influence the prognosis.Quantitative pathologic technique combined with valid statistical methods, as an objective means of assessing prognosis, may reliably improve the outcome in lymph node negative breast cancer.